Cyclacel Pharmaceuticals, Inc. CYCCP
At closeSep 11, 2025, 4:00 PM EDT
- Market cap
- 11.31M
- Revenue (ttm)
- 80.00K
- Shares out
- 12.50M
- Dividend
- 0.60
- Ex-dividend date
- Jan 18, 2024
- Volume
- 6.46K
- Avg volume
- 380
- Open
- 5.35
- Previous close
- 5.05
- Day's range
- 5.05 – 5.43
- 52-week range
- 5.05 – 5.60
- Beta
- 0.56
Key statistics
- Enterprise value
- 6.05M
- PEG ratio
- 0.00
- Price / sales
- 153.78
- Price / book
- 11.29
- Dividend yield
- 9.84%
- Payout ratio
- 0.00%
- Revenue growth
- -98.90%
- Free cash flow
- -7.66M
- Total cash
- 6.00M
- Total debt
- 5.00K
- Return on equity
- -570.69%
- Short % of float
- 0.00%
- 50-day average
- 6.68
- 200-day average
- 9.38
Next earnings
Consensus EPS estimate 0.00.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cyclacel.com
News
Your note
Sign in to keep a note on CYCCP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sound Income Strategies, LLC | 7.47% | 94 | 608 | Sep 29, 2024 |